P-21
Cerebrolysin-inspired neurogenic peptide designed to enhance BDNF signaling and promote hippocampal neurogenesis
P-21 (also referred to as P21) is a small tetrapeptide developed by researchers studying the active fractions of Cerebrolysin. It was designed to replicate and amplify the neurogenic properties of Cerebrolysin's low-molecular-weight peptide fraction by specifically targeting BDNF signaling and hippocampal neurogenesis.
P-21 acts by binding to a site on the NCAM (Neural Cell Adhesion Molecule) receptor that amplifies BDNF/TrkB signaling without directly binding to TrkB itself. This mechanism promotes neurogenesis, synaptic plasticity, and neuroprotection. Animal studies have shown that P-21 significantly increases hippocampal cell proliferation, improves spatial memory in aged rodents, and protects against neuroinflammation.
P-21 is not approved for clinical use and human data is absent — it remains a research compound. However, it has attracted interest among neurohackers for its targeted BDNF-enhancing mechanism and its connection to the well-established Cerebrolysin research base.
Primary Benefits
Synthetic ACTH analog developed in Russia, enhances BDNF production and cognitive performance
Synthetic analog of tuftsin with anxiolytic and nootropic effects, no dependency or tolerance risk
HGF/MET signaling amplifier and among the most potent synaptogenic nootropics studied — note: foundational study retracted April 2025